NUVB Nuvation Bio Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 1811063 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY654.2%
TTM net income YoY37.5%
TTM EPS YoY20.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-61.2%
Net margin-67.4%
FCF margin—
EBITDA margin-60.1%
Returns
ROE-49.1%
ROA-19.7%
ROIC (approx.)-30.5%
Asset turnover0.29x
Leverage & solvency
Liabilities / assets70.7%
Debt / equity1.25x
Current ratio7.45x
Interest coverage-5.87x
Cash quality & payout
Operating cash flow / net income0.78x
Accruals ratio-4.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $62.90M | $7.87M |
| Cost of revenue | — | $7.08M |
| Gross profit | — | $795,000 |
| R&D expense | $115.11M | $99.12M |
| SG&A expense | $151.56M | $69.23M |
| Operating income | -$213.06M | -$592.63M |
| Interest expense | $13.68M | $341,000 |
| Pretax income | -$204.63M | -$567.94M |
| Income tax | $0 | $0 |
| Net income | -$204.63M | -$567.94M |
| EBITDA | -$211.32M | -$591.94M |
| EPS (basic) | -0.60 | -2.11 |
| EPS (diluted) | -0.60 | -2.11 |
| Weighted avg. shares (diluted) | 341,541 | 268,772 |
| Balance sheet | ||
| Cash & equivalents | $164.09M | $35.72M |
| Short-term investments | $365.12M | $466.97M |
| Inventory | $11.41M | $0 |
| Current assets | $571.52M | $526.25M |
| PP&E, net | $564,000 | $586,000 |
| Intangibles | $11.21M | $4.62M |
| Total assets | $594.82M | $540.63M |
| Current liabilities | $82.23M | $58.24M |
| Short-term debt | $5.72M | $6.28M |
| Long-term debt | $47.21M | — |
| Total debt | $52.93M | — |
| Total liabilities | $289.11M | $76.84M |
| Shareholders' equity | $305.72M | $463.79M |
| Net debt | -$111.15M | — |
| Shares outstanding | 346.50M | 337.84M |
| Cash flow statement | ||
| Operating cash flow | -$173.43M | -$130.41M |
| Capital expenditure | $8.00M | $0 |
| Free cash flow | -$181.43M | -$130.41M |
| Investing cash flow | $99.52M | $122.70M |
| Financing cash flow | $202.53M | $331,000 |
| Depreciation & amortization | $1.74M | $683,000 |
| Stock-based compensation | $35.89M | $32.27M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.